BioMarin Pharmaceutical gained almost $1 billion in market cap on strong positive data for its gene therapy to treat severe hemophilia A.

Specialty pharma InnoPharma was acquired by Pfizer a few years ago for up to $360 million. Now, the team behind that effort is at it again with another…

Unlikely IPO candidate Kadmon made it out in a tough IPO market amid swirling criticisms of its rather infamous current and former management, namely the…

Building on the original 2013 R&D deal between Japan’s Astellas and Cytokinetics, the two have now expanded their initial collab, which will see Astellas…

Merck has shocked ALK-Abello by returning the rights to three sublingual allergy immunotherapy tablets, triggered an 18% drop in the Danish firm's share…

We can rebuild him; we have the technology--but Americans question if we should in a new survey designed to assess attitudes to modern biotechnology advances.

This year will be the year of the woman exec in biotech, no doubt about it.

Kite Pharma has always been focused on engineering a patient’s own T cells to treat their cancer. But now, it’s in-licensed tech to create off-the-shelf T-cell…